Meniscus Arrow

Meniscus Arrow™

A bioresorbable fixation device for arthroscopic repair of bucket-handle tears of the meniscus.
References in periodicals archive ?
Outcomes after meniscal repair using the meniscus arrow in knees undergoing anterior cruciate ligament reconstruction.
Both complaints charge infringement of a patent covering the company's Meniscus Arrow.
Year-to-date Meniscus Arrow revenues accounted for 68% of total product revenues, compared with 70% during the first nine months of 1997.
Second quarter 1998 Meniscus Arrow sales represented 66% of total sales, down (on a percentage basis) from 67% during the 1997 second quarter.
David Anderson, the President and Chief Executive Officer of Bionx Implants, commented: "Our fourth quarter reflects another strong quarter of sales of our Meniscus Arrow products, as well as growth in fracture management implants.
Our sales increased substantially for both our Meniscus Arrow products and for our non-Arrow products (primarily pins, screws, and instruments).
The company is already both profitable and cash-flow positive, reflecting the success of its Meniscus Arrow.
Carlozzi explains, "When the Meniscus Arrow was introduced, the company's sales more than doubled in a very short period of time.
biowchlanialne screws, set to reconstruct wiazadal, implants, plates, needles nitrinolowe, sterile marker, resektor, forage side electrode to remove tissue, the meniscus arrow sewing, drains Single-cutters arthroscopic shaver, gaskets External catheters, disposable blades, cement, implants for hip replacement knee, knee replacement, walk with the antibiotic into the knee joint inspection grid, the pan antyluksacyjna, a system for uncemented revision hip acetabular implants, carbon, screws, plates for fixation of bone implants quilting graft material, sewing kits menisci.
Deteriorating outcomes after meniscal repair using the Meniscus Arrow in knees undergoing concurrent anterior cruciate ligament reconstruction: increased failure rate with long-term follow-up.
Sales of the Meniscus Arrow, which experienced declines in previous years, stabilized during 2001 at approximately a 45% market share level, as estimated by the Company.
The investigators found that surgical time was cut in half using the meniscus arrow, and that "there was no statistical differences in healing (total and partial) between arrows and sutures in the subgroups with isolated lesions, lesions in ACL-reconstructed knees, and lesions in ACL-insufficient knees.